Adjuvant therapy for pancreatic neuroendocrine tumors – Expert consensus and recommendations for future research

#3882

Introduction: With the increase of incidentally diagnosed pancreatic neuroendocrine tumors (panNEN), more patients are treated with curative intent. Survival in patients with a panNEN is impacted by the development of recurrence, but postoperative adjuvant therapy is not yet recommended in guidelines due to absence of evidence. Multiple clinicopathological characteristics have been described in literature to identify patients at high-risk of recurrence who might benefit from adjuvant treatment. Since panNEN are rare tumors, prospective randomized controlled studies on the role of adjuvant therapy in these patients have not been performed.

Aim(s): The PanNEN Consensus Study Group was established to overcome some of these obstacles and aims to boost future investigations by providing expert opinions on issues essential for the design of clinical trials.

Materials and methods: Through online surveys and a subsequent meeting during the 2017 ENETS Conference, international experts on pancreatic NEN treatment formulated priorities for future studies on adjuvant treatment after curative resection of well-differentiated panNEN. Priority was given to the development of well-designed clinical trials with clearly defined efficacy criteria.

Conference:

Presenting Author: Heidsma C

Authors: Heidsma C, Engelsman A, Klümpen H, Falconi M, Frilling A,

Keywords: pancreatic neuroendocrine tumor, recurrence, adjuvant therapy, prevention, expert consensus, future research,